Molecular testing for the management of indeterminate thyroid nodules

Area of Science:

• Endocrinology
• Oncology
• Cytopathology

Background:

• Thyroid nodules affect up to 70% of the population, with a 5-10% malignancy rate.
• Fine-needle aspiration (FNA) and the Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) aid in nodule risk stratification.
• Indeterminate thyroid nodules (ITN), diagnosed as atypia of undetermined significance (Bethesda III) or follicular neoplasm (Bethesda IV), present management challenges due to intermediate malignancy risk (16-48%).

Purpose of the Study:

• To review commercial molecular tests (MT) for improving the risk stratification of indeterminate thyroid nodules (ITN).
• To provide practical guidance on interpreting molecular test results for thyroid nodules.
• To discuss future directions in molecular testing for thyroid nodule evaluation.

Main Methods:

• Review of current literature on molecular tests for thyroid nodule risk stratification.
• Analysis of the utility of molecular tests in managing indeterminate thyroid nodules (ITN).
• Discussion of diagnostic challenges and management strategies for ITN.

Main Results:

• Molecular tests (MT) have emerged as valuable tools to enhance the risk stratification of indeterminate thyroid nodules (ITN).
• These tests aid in differentiating benign from malignant nodules, thereby reducing the need for unnecessary surgeries.
• Interpretation of MT results is crucial for effective clinical decision-making.

Conclusions:

• Molecular tests (MT) significantly improve the management of indeterminate thyroid nodules (ITN) by providing more accurate risk assessment.
• Guidance on interpreting MT results is essential for clinicians to optimize patient care and reduce surgical intervention.
• Future advancements in molecular diagnostics hold promise for further refining thyroid nodule evaluation.